<DOC>
	<DOCNO>NCT02658838</DOCNO>
	<brief_summary>The purpose study determine ticagrelor combine low molecular weight heparin effective safe PCI .</brief_summary>
	<brief_title>The Application Ticagrelor Combined With Low Molecular Weight Heparin During PCI</brief_title>
	<detailed_description>Ticagrelor new drug compare clopidogrel . It strong antiplatelet capacity . After PCI，whether use low molecular weight heparin make patient good prognosis , What 's more，full amount half amount low molecular weight heparin ? , also investigator want explore whether may lead bleed event .</detailed_description>
	<mesh_term>Calcium heparin</mesh_term>
	<mesh_term>Heparin , Low-Molecular-Weight</mesh_term>
	<mesh_term>Dalteparin</mesh_term>
	<mesh_term>Heparin</mesh_term>
	<mesh_term>Ticagrelor</mesh_term>
	<criteria>1 . Age ≥18 year old ≤75 year ; 2. unstable angina , nonST segment elevation acute myocardial infarction , old myocardial infarction , confirm presence myocardial ischemia ; 3. voluntary participation clinical trial , informed consent ; 1. acute ST segment elevation myocardial infarction , stable angina pectoris ; 2. aspirin allergy resistance ; 3. consolidated stroke , chronic obstructive pulmonary disease ticagrelor contraindication ; 4. patient coagulopathy ; 5. continue one year aspirin treatment dual antiplatelet ticagrelor ; 6. complete revascularization ; 7 . NYHA ≥Ⅲ level leave ventricular ejection fraction &lt; 40 % ; 8. severe liver kidney dysfunction ( ALT AST three time upper limit normal , creatinine clearance le 30ml / min1.1.72m2 ) ;</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>August 2015</verification_date>
</DOC>